Physician profile
Sadia Khan
NPI 1881633048
$4,068.40
in general payments reported to CMS, 2019-2025
42 companies · $1,055 in 2025
The $1,055 reported for 2025 was more than what 86% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $463 · 2020: $113 · 2021: $382 · 2022: $426 · 2023: $750 · 2024: $879 · 2025: $1,055.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,684.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,684.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $528.91 | 2019-2025 | Breztri, Airsupra, Lokelma |
| Otsuka America Pharmaceutical, INC. | $477.28 | 2023-2025 | Rexulti, Nuedexta |
| Janssen Pharmaceuticals, INC | $321.76 | 2019-2024 | Xarelto |
| Novo Nordisk INC | $297.27 | 2022-2025 | Rybelsus, Ozempic, Wegovy |
| Axsome Therapeutics, INC. | $278.83 | 2025 | Auvelity |
| Lilly USA, LLC | $206.46 | 2021-2025 | Mounjaro, Jardiance, Zepbound |
| Bayer Healthcare Pharmaceuticals INC. | $174.66 | 2022-2025 | |
| Biogen, INC. | $153.34 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $117.03 | 2021-2024 | Xifaxan |
| Boehringer Ingelheim Pharmaceuticals, INC. | $109.15 | 2021-2024 | Jardiance, Ofev |
| Teva Pharmaceuticals USA, INC. | $104.14 | 2022-2025 | Austedo Xr, Austedo Xr |
| Astellas Pharma US INC | $98.47 | 2019-2023 | Veozah |
| Sumitomo Pharma America, INC. | $91.75 | 2023-2025 | Gemtesa |
| Lundbeck LLC | $82.29 | 2023-2025 | Rexulti |
| Scpharmaceuticals INC. | $81.55 | 2024-2025 |
Show all 42 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sadia Khan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.